Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. - Oza, Amit M; Matulonis, Ursula A; Malander, Susanne; Hudgens, Stacie; Sehouli, Jalid; del Campo, Josep M; Berton-Rigaud, Dominique; Banerjee, Susana; Scambia, Giovanni; Berek, Jonathan S; Lund, Bente; Tinker, Anna V; et al. (Lancet Oncology, 2018)